low severity
Observed headline efficacy anchor
Wegovy injection now has a headline efficacy anchor of 15% at Week 68.
semaglutide · GLP-1 receptor agonist
Wegovy injection
Preserves the split between label-safe PI efficacy and Novo headline language.
Live fetch
Basis split
Why are there two numbers?
Novo shows the PI mean percent weight loss as the label-safe anchor and a rounded headline on the public results page. The PI number should stay primary in comparisons.
Efficacy anchors
2 anchors
Label-safe anchor
LabelWeek 68Trial: Study 2
Adults with obesity, or with overweight and at least one weight-related condition
Why this number?
PI anchor for the core adult obesity study at Week 68.
Dose context: 2.4 mg once weekly
Consumer headline
HeadlineWeek 68Trial: Study 2
Adults with obesity, or with overweight and at least one weight-related condition
Why this number?
Patient-facing Wegovy page rounds the core pen result to about 15% weight loss.
Dose context: 2.4 mg once weekly
Price anchors
2 anchors
Intro self-pay
IntroDose context: 0.25 mg/0.5 mL
Program: NovoCare self-pay program
Why this number?
First 2 months, new patients only
Self-pay new-patient program pricing
Patient segment: cash_pay_new_patient
First 2 months, new patients only
Maintenance self-pay
MaintenanceDose context: 0.5 mg/0.5 mL
Program: NovoCare self-pay program
Why this number?
Standard self-pay program pricing
Patient segment: cash_pay
Source ledger
3 linked
backs: Intro self-pay, Maintenance self-pay
backs: Consumer headline
backs: Label-safe anchor
Timeline
Change history
low severity
Observed label-safe efficacy anchor
Wegovy injection now has a label-safe efficacy anchor of 14.9% at Week 68.